GlassScriptPhysician profile
Naeem A Lughmani
NPI 1013915263
$16,624.48
in general payments reported to CMS, 2019-2025
33 companies · $2,867 in 2025
The $2,867 reported for 2025 was more than what 91% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $1,540 · 2021: $2,019 · 2022: $2,875 · 2023: $3,116 · 2024: $2,954 · 2025: $2,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,250 · Education: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,249.85 |
| Education | $687.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,711.09 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Jazz Pharmaceuticals INC. | $2,618.16 | 2019-2025 | |
| Harmony Biosciences LLC | $2,380.68 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $2,132.77 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,164.82 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Axsome Therapeutics, INC. | $956.04 | 2022-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $766.85 | 2023-2025 | Lumryz |
| Mylan Specialty L.P. | $672.71 | 2019-2024 | Yupelri |
| Genzyme Corporation | $460.63 | 2021-2025 | |
| Amgen INC. | $387.23 | 2021-2025 | Tezspire |
| Insmed, INC. | $336.09 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $297.95 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $250.57 | 2022-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $248.20 | 2023-2025 | Dupixent |
| Eisai INC. | $243.69 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $165.18 | 2021-2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $153.98 | 2024-2025 | |
| Pfizer INC. | $124.33 | 2023 | |
| Sunovion Pharmaceuticals INC. | $95.47 | 2019 | |
| Viatris Specialty LLC | $87.11 | 2025 | Yupelri |
| Circassia INC. | $57.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $46.24 | 2021-2022 | |
| Verona Pharma, INC. | $43.29 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $41.32 | 2022-2024 | Quviviq |
| Inspire Medical Systems, INC. | $33.65 | 2024 | Inspire |
| Pulmonx Corporation | $30.28 | 2021-2022 | |
| Resmed Corp | $27.32 | 2019-2020 | |
| 3b Medical, INC. | $17.40 | 2024 | Luna |
| Advanced Respiratory, INC | $15.89 | 2019 | |
| Philips North America LLC | $15.87 | 2020 | |
| Fisher & Paykel Healthcare INC | $15.61 | 2025 | Fisher & Paykel Healthcare |
| Baxter Healthcare | $13.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Lughmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.